Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (639)	2/17/2000 1:11:00 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 52153

Peter, have been looking at Elan recently. Has market cap of about $9.5B, $1B in cash and another $1B in equity holdings in cyto, tgen, lgnd, emis and a host of other companies with lower market caps. The company seems poised to grow with several drugs pending FDA approval. It had $1B in sales last year and analysts project they can double those sales within 3 years. Have you looked at Elan before? Any opinion? Value sure is hard to find now. GLIA, ELAN and another company that shall remain nameless for now (still researching, Rick) are the only reasonably valued biopharms on my radar.